Gilead news and events in 2026
Gilead is a biopharmaceutical organization that researches and develops therapeutic treatments. The organization focuses on creating antiviral medications for the treatment of conditions such as HIV, hepatitis B, hepatitis C, influenza, and respiratory viruses.
Public (GILD)Biotechnology Research10,000+ employeesgilead.comLinkedIn
Get Gilead's live signals in Claude or ChatGPT, or by API
What changed at Gilead this week? Use Autobound signals for gilead.com.- Dated updates
- 68
- Last event
- Oct 29, 2026
- Open rolesSnapshot Nov 3, 2026
- 61
- Latest SEC filing
- Oct 29, 2026
Source: Autobound Signal API · 68 signals tracked for Gilead · updated
Overview
Gilead by topic
110-K filing
61open roles
1reported layoff round
1executive move
40+signals
23 in the last 90 days
- Glassdoor15+
- Website changes9
- Employee growth7
- Patents4
- and 2 more sources
Latest events
Latest Gilead events
Showing 10 of 19 events. The Signal API returns all of them.
Get them with one API call- In developmentGilead reports trial success. Gilead Sciences stock is valued at USD 189.8 billion graduallyGilead reported positive Phase 2 clinical trial results for its investigational oral emvistegrast treatment for ulcerative colitis and plans to launch a Phase 3 study in 2027.
- In developmentGilead Sciences stock reports growth at EUR 133.42, plus 0.02 percentGilead Sciences is developing oral treatments for mosquito-borne flaviviruses, supported by a new federal grant.
- New location
- Facility expansionGilead opens new building on existing Foster City campusGilead Sciences unveiled a new 182,000 square-foot building on its existing campus in Foster City, which will house oncology and scientific research.
- In developmentGilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play?Gilead Sciences is developing Yeztugo, a once-weekly oral HIV pre-exposure prophylaxis (PrEP) with a PDUFA target date of Feb. 2.
- Partnership
- LaunchFDA approves daily HIV pill from Gilead designed to simplify treatment for some patientsGilead Sciences launched its new once-daily HIV pill, Bixlenvo, after receiving approval from the U.S. Food and Drug Administration.
- EarningsGilead's Second-Quarter Revenue Rises 8%, Exceeding Wall Street ForecastsGilead Sciences reported an adjusted loss per share of $6.75 for the second quarter, better than the analyst consensus expectation of a $7.24 loss.
- LaunchWill the Label Expansion of Trodelvy Strengthen GILD's Oncology Portfolio?Gilead Sciences received FDA approval for the label expansion of its breast cancer drug Trodelvy for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC).
- In development
Showing 10 of 19 events. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Gilead with the Signal API
One POST /v1/companies/enrich call with gilead.com returns every signal type for Gilead, each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"gilead.com","limit":20}'Bulk data
Need these signals for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file).
Same industry
Companies related to Gilead
Gilead questions
What is the latest news on Gilead?
What is going on with Gilead?
Is Gilead laying off employees?
What else does Autobound track for Gilead?
Is Gilead hiring right now?
Page updated , the date of the newest row on this page.
Source. News, SEC filings (8-K, 10-K, 10-Q, Form D), hiring data and other signals (Reddit, podcasts, Glassdoor, reviews, social posts, patents, web traffic) from the Autobound Signal API.
Method. Stories are grouped when they report the same event within 14 days. Rows that do not name the company are removed. Each row links its source.
Data as of .